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Wehavedevelopedaseriesofaminoacetylenicisoindoline-1,3-dionecompoundsandshowedtheiranti-inﬂammatoryactivitiesby
reducing carrageenan-induced rat paw edema and modulating proinﬂammatory and anti-inﬂammatory cytokines. In the present
study and due to eﬃcacy reasons, we are exploring only two of these compounds, namely, ZM4 and ZM5, to reveal their analgesic
activity and toxicity. Following oral administration, both compounds were eﬀective in reducing signiﬁcantly (P<0.05–0.001)
acetic acid-induced writhing behavior, hot plate latency test, and formalin-induced paw licking time as antinociceptive indicators
in mice and rats, respectively. Regarding the toxicity, the acute (20, 50, and 150mg/kg) and repeated oral administration (10,
20, and 50mg/kg) of these compounds for ten days did not produce any mortality and the compounds were considered well
tolerated. However, repeated oral administration of 50mg/kg of both compounds induced erythropoiesis by means of increasing
signiﬁcantlyredbloodcells,hemoglobin,andpackedcellvolume.Moreover,thesecompoundsdidnotinducegastriclesionsinthe
stomach of experimental animals at the doses that exhibited analgesic and anti-inﬂammatory activity compared to indomethacin
as a positive control. The results indicate that ZM4 and ZM5 possess potential analgesic activity while being preliminarily safe and
have minimal ulcerogenic activity.
1.Introduction
Cyclooxygenase (COX) plays an important role in the pro-
duction of prostaglandins and the release of chemical pain
mediators; therefore, inhibiting COX will reduce the painful
response resulting from the prostaglandin cascade [1]. As
inhibitors of COX enzyme, nonsteroidal anti-inﬂammatory
drugs (NSAIDs) have been widely used to treat inﬂamma-
tion, mild-to-moderate pain, and fever. There are at least
three isoforms of the COX enzyme: COX-1, COX-2, and
COX-3 [2, 3]. COX-1 is expressed constitutively throughout
the body and is important in maintaining vital functions
such as glomerular ﬁltration rate, platelet function, and gas-
tric mucosal protection. COX-2, on the other hand, is unde-
tectable in most normal functioning tissues [4]. However,
the expression of COX-2 is induced as a response of inﬂam-
mation whereas COX-3 was observed to be abundant in
the cerebral cortex [2, 3] .A l lN S A I D sh a v eas i m i l a re ﬀect
on reducing pain [5, 6]. These include the selective NSAID
or COX-2 inhibitor, Celecoxib, nonselective NSAIDs, such
as ibuprofen and aspirin, and partially selective NSAIDs,
suchasmeloxicam,nabumetone,andetodolac.Nevertheless,
nonselective inhibition of COX enzyme can prevent the pro-
duction of physiologically important prostaglandins which
protect the gastric mucosa from damage by hydrochloric
acid, maintain kidney function, and aggregate platelets when
required[7].Forthat,mostofthecurrentresearchisdirected
toward developing selective COX-2 inhibitors in order to
minimize the side eﬀects associated with the use of the non-
selective NSAIDs. However, COX-2 inhibitors were associ-
ated with cardiovascular diseases that halted the possibility
of their long-term use.
Therefore, we have developed new chemical compounds
that incorporate isoendoline-1,3-dione and acetylenic
derivatives to induce anti-inﬂammatory and analgesic acti-
vities, respectively [8–11]( Figure 1). In addition, we2 ISRN Pharmacology
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Figure 1: Chemical structures of ZM4 and ZM5.
incorporated acetylenic group in order to increase the
selective inhibition toward COX-2 isoform [12]. This unique
combination represents a new series of compounds as
potential anti-inﬂammatory agents as has been shown to
reducecarrageenan-inducedpawedemaandstructurallydif-
fers from the generally used drugs that contain acidic, enolic,
sulfonamide, or sulfon groups which should exclude the
direct insult on the gastrointestinal [11]. Of all the molecules
reported in our previous studies, ZM4 and ZM5 were found
to possess the best COX-2 inhibition activities, better in
reducing carrageenan-inducing inﬂammation, and modu-
late proinﬂammatory and anti-inﬂammatory cytokines
[11, 13, 14] and therefore were selected for further eﬃcacy
and safety investigations. The aim of the present study there-
fore is to study the analgesic activity of these compounds in
addition to studying their toxicity and ulcerogenic eﬀect on
the stomach following single and repeated administration.
2.MaterialsandMethods
2.1. Drugs and Chemicals. The compounds, namely, ZM4
and ZM5 were synthesized and characterized as described by
Al-Qaisietal.[11].Ibuprofensodiumanddiclofenacsodium
were kindly provided by the Jordanian Pharmaceutical Man-
ufacturing Co. “JPM” (Naor, Jordan). Celecoxib as Celebrex
of 200mg capsules (Pﬁzer Inc, USA) and acetylsalicylic acid
as Aspirin of 300mg tablets (Bayer AG, Germany) were
utilized in the experiment. Glacial acetic acid was purchased
from Medex, UK. Formaldehyde solution (formalin) was
obtained from Merck, Germany.
2.2. Animals. Sprague Dawley rats (180–280g) and Balb/c
mice (20–28g) were obtained from Yarmouk University
Animal House Unit (Irbid, Jordan) and housed in Petra Uni-
versity Animal Care Unit (Amman, Jordan). Animals were
accommodated in a 12hr light/dark cycle and a temperature
of 20 ± 2◦C. All animals were acclimatized for at least 5
days prior to experiments with free access to standard diet
and drinking water. Animal experiments were performed in
compliance with FELASA guidelines (Federation of Euro-
pean Laboratory Animal Science Association) following pro-
tocols approval by the Ethical Committee of the Faculty of
Pharmacy and Medical Sciences, Petra University, Jordan
(Doc 4/2009).
2.3. Writhing Induction and Quantiﬁcation. ZM compounds
(25 and 50mg/kg) dissolved in 0.1N HCL followed by soni-
cationat40◦Cfor5minandaspirin(200mg/kg)dissolvedin
0.9% saline as a reference positive control were administered
orally 1 hour before intraperitoneal injection of 0.6% acetic
acid solution (10mL/kg) to 4 hours fasting mice. The mice
were then kept individually in glass cages for observation,
and the number of abdominal contractions (writhing move-
ments) was counted for the next 20min for each mouse.
The data represent average of the total number of writhings
observed.
2.4. Hot Plate Latency Test. Mice were divided into 4 groups
as the following: Group l, received saline solution (control);
Group 2, received aspirin (200mg/kg) as a positive control;
Group 3 received ZM4 (20mg/kg); Group 4 received ZM5
(20mg/kg). Fifteen minutes after oral administration of
the treatments, the mice were separately placed in a glass
chamber mounted on a hot plate that was maintained at
52 ± 0.5◦C as described elsewhere [15]. Initially, the mice
that showed nociceptive responses within 12 seconds were
only used for the subsequent experiments. The time between
the placement of the mouse on the hot plate and the occur-
rence of the licking of hind paws was recorded as response
latency.Thenociceptiveresponsewasmeasuredevery15min
over a 60min period. The cut-oﬀ time was 45 seconds.
Data are presented as mean % latency change calculated
for each mouse by dividing the initial latency (beforeISRN Pharmacology 3
treatment) by the latency determined at diﬀerent time inter-
vals posttreatment multiplied by 100.
2.5. Formalin-Induced Paw Licking. ZM compounds were
prepared as mentioned earlier. Ibuprofen sodium, as a posi-
tive control, was dissolved in 0.9% saline followed by son-
ication [16] .A d u l tr a t sw e r ep r e t r e a t e do r a l l ya sf o l l o w s :
Group l, served as a negative control group receiving 0.9%
saline solution (0.5mL/g body weight); Group 2, ibuprofen
(20mg/kg) as a positive control; Group 3, received ZM4
(20mg/kg); Group 4, received ZM5 (20mg/kg). Thirty min-
utes after treatment, each rat was injected with 50μLo f
2.5% solution of formalin subcutaneously under the plantar
surface of the left hind paw. The injected rats were placed
separately in mirror glass chambers for observation. The
time spent for licking the injected paw was recorded, and the
datawereexpressedastotallickingtimeintheearlyphase(0–
5min) and the late phase (15–30min) after formalin injec-
tion [17, 18].
2.6. Toxicity Studies
2.6.1. Acute Toxicity Testing of ZM4 and ZM5. Female Balb/c
mice (20 ± 2g) were used for acute toxicity testing of the
synthesized compounds. Oral and intraperitoneal routes
of administration were investigated for ZM4 and ZM5
compounds at three dose levels (20, 50, and 150mg/kg) and
compared to control groups that received only vehicle. At the
day of experiment, 4 hours fasting mice were grouped and
administered freshly prepared compounds. The mice were
continuously observed for 4 hours following administration
to detect changes in the autonomic or behavioral responses
and then monitored for any mortality for the following 14
days. In case of any death, an autopsy setup was prepared for
gross organ inspection followed by histopathological investi-
gation of any abnormal tissue.
2.6.2. Subacute Toxicity Testing of ZM4 and ZM5. Rats of
both sexes were used for subacute toxicity testing following
an oral route of administration of ZM4 and ZM5 at three
dose levels (10, 20, and 50mg/kg) and compared to control
groups that received only vehicle. Rats were maintained in
clean cages and had free access to food and water. The treat-
ments were administered to the rats by oral gavages for
ten days, and all rats were weighed daily. The animals were
observed for clinical symptoms daily after 1 hour of treat-
ment. At the end of the experimental period the rats were
sacriﬁced and blood samples were obtained by cardiac punc-
ture for hematological and serum biochemical analysis (only
for control and 50mg/kg). Autopsy was performed for all
rats and the major organs; namely, liver, spleen, two kidneys,
heart, and lungs were removed and accurately weighed.
2.6.3. Ulcerogenic Activity of the Synthesized Compounds.
Rats were divided into 4 groups (n = 5) and received the
following treatments: Group l received 4mL/kg saline solu-
tion (control); Group 2 received indomethacin 20mg/kg as a
positive control; Group 3 received ZM4 (20mg/kg); Group 4
received ZM5 (20mg/kg). Fasting rats (16 hours) were orally
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Figure 2: Reduction of acetic acid-induced writhing response in
mice following treatment with aspirin, ZM4, and ZM5. Values are
expressed as mean ± S.E.M. (n = 9). Symbols represent statistical
signiﬁcance against 0mg/kg dose as ∗P<0.05, ∗∗P<0.01, and
∗∗∗P<0.001.
administered the compounds, saline or indomethacin once
daily for 3 consecutive days. On the fourth day the animals
were sacriﬁced by an overdose of ether, and the stomach was
quickly dissected, cut along the lesser curvature, and washed
with saline. The gastric mucosa was examined using a hand
held microscope (10x) for the presence of gastric irritation.
Ulcers were scored using arbitrary scale where 0 = no lesion,
0.5 = hyperaemia, 1 = one or two slight lesions, 3 = very
severe lesions, and 4 = mucosa full of lesions. Ulcer index
(UI) was calculated as mean ulcer scores ± SEM [19].
2.7. Statistical Analysis. Results are expressed as mean ±SEM
for each group. Data were assessed by one-way ANOVA,
followed by one-tailed Dunnett’s t-test (SPSS 17, USA). P
value <0.05 was considered signiﬁcant.
3. Results
3.1. Writhing Test. Ad o s e - d e p e n d e n tp r o t e c t i v ee ﬀect
against writhing behavior was observed in mice treated with
ZM4 and ZM5 (Figure 2). Signiﬁcant reductions of writhing
behavior were seen in mice treated with ZM4 (50mg/kg)
and ZM5 (25 and 50mg/kg). The highest reduction was
observed in mice treated with high dose of ZM5 (P<
0.001). Similarly, aspirin at 200mg/kg signiﬁcantly inhibited
the writhing episodes (P<0.01) but this reduction was
not signiﬁcantly diﬀerent than ZM4 and ZM5 treated mice
(Figure 2).
3.2. Hot Plate Test. The results of the hot plate test show that
oral administration of aspirin (200mg/kg), ZM4, and ZM5
(bothat20mg/kg)producedasigniﬁcant(P<0.05)increase
in latency times especially at 45–60min after adminis-
tration (Figure 3). It was noticed that ZM4 showed a fast
onset of action and increased signiﬁcantly the % of latency4 ISRN Pharmacology
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Figure 3: Percent of increase in latency periods of mice treated with
normal saline (negative control), aspirin (positive control), ZM4,
and ZM5. Treated mice were challenged on a hot plate every 15min
for 1 hour after oral treatment. Values are expressed as mean ±
S.E.M (n = 9). ∗P<0.05, and ∗∗P<0.01 against normal saline
and +P<0.05 ZM4 and ZM5 against aspirin.
period after 15min of administration. The eﬀect of ZM4
continued to increase in a linear-like pattern during the test-
ingperiodwhereitincreasedthelatencyperiodby82%com-
pared to the recorded initial latency periods at the end of
60min testing time (P<0.01). Both ZM4 and ZM5 showed
more pronounced eﬀects than aspirin (200mg/kg). How-
ever, a statistically signiﬁcant diﬀerence between the tested
compounds and the positive control was detected only after
60min of the oral administrations (Figure 3).
3.3. Formalin Test. Formalin administrations produce a
typical pattern of two-phase pain response. The ﬁrst phase
(early, acute phase) starts immediately after administration
of formalin and diminishes within 10min whereas the sec-
ond phase (late, tonic phase) starts at 15min after formalin
administration and lasts for 30min after pain induction [17–
19]. The ﬁrst and the second phases of formalin test cor-
respond to neurogenic and inﬂammatory pain, respectively
[18, 20].
ZM4 at 20mg/kg caused a signiﬁcant antinociceptive
eﬀect by decreasing the licking time in both early and late
phase (P<0.001 and P<0.05, resp.) similar to ibuprofen at
20mg/kg (Figure 4). On the other hand, ZM5 caused a signi-
ﬁcant eﬀect at early phase (P<0.001) but not at the late
phase (P>0.05).
3.4. Toxicity Studies. No mortality was observed following
the acute administration of 20–150mg/kg of ZM4 and ZM5.
In addition, animals did not show any change in the auto-
nomicorbehavioralresponsesduringtheobservationperiod
up to the 14th day of monitoring.
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Figure 4: Nociceptive behavior of rats in the early phase (0–5min)
and late phase (15–30min) after injection of formalin recorded
as amount of time (s) spent licking the injected paw following
treatment with ibuprofen, ZM4, and ZM5 (all at 20mg/kg dose).
Values are expressed as mean ± S.E.M. (n = 8). Symbols represent
statistical signiﬁcance against control group as ∗P<0.05 and ∗∗P<
0.001.
Following a 10-day repeated administration, no signif-
icant eﬀect of ZM4 and ZM5 on the animal weights was
observed in comparison to control rats (P>0.05). In addi-
tion, there was no signiﬁcant eﬀect of ZM4 and ZM5 at
dose of 50mg/kg on the liver, spleen, kidneys, and heart
weights when compared to control. However, only the lungs’
weight in female treated rats was signiﬁcantly (P<0.01)
less than control animals, but no gross abnormalities were
observed. As for the hematological parameters, ZM4 and
ZM5compoundsatdoseof50mg/kgmarkedlyincreasedred
blood cells (RBC), hemoglobin (Hb), and packed cell vol-
ume (PCV) values (P<0.01–0.001) with a slight decrease in
mean corpuscular volume (MCV), no change in the mean
corpuscular hemoglobin (MCH), and mean corpuscular
hemoglobin concentration (MCHC) of male or female
rats. Furthermore, no signiﬁcant change in total WBC or
lymphocyte and monocyte counts was observed (Table 1).
In addition, there was no signiﬁcant change in clinical bio-
chemistry values such as glucose, GOT, GPT, GGT, alkaline
phosphates, urea, cholesterol, total protein, and albumin
(Table 2). whereas a 10-day repeated administration of ZM5
(50mg/kg) in females increased signiﬁcantly creatinine and
triglyceride serum levels (P<0.05).
3.5. Ulcerogenic Activity of the Synthesized Compounds. The
gastric eﬀects of oral administration of ZM4 into rats were
similar to normal saline administered control group (0.2 ±
0.1UI for both treatments). However, oral administration of
ZM5 into rats induced a minimal hyperemia (0.4 ± 0.1UI)
in comparison to severe full mucosal ulcers induced by
20mg/kg indomethacin (3 ±0.4UI)(Figure 5).ISRN Pharmacology 5
Table 1: Rats hematological parameters following a 10-day administration of ZM4 and ZM5.
Parameter Control ZM4 50mg/kg ZM5 50mg/kg
Males Females Males Females Males Females
RBC (×106/μL) 5.5 ± 0.2 5.4 ± 0.3 6.2 ± 0.1∗ 8.4 ± 0.8∗ 9.0 ± 0.1∗ 8.3 ± 0.5∗
HB (g/dL) 14.3 ± 0.4 14.2 ± 0.6 15.2 ± 0.3 21.2 ± 1.6∗∗ 21.5 ± 0.2∗∗ 20.1 ± 1.1∗∗
PCV (%) 29.6 ± 0.2 29.4 ± 1.0 31 ± 0.6∗ 42.9 ± 3.3∗ 43.6 ± 0.5∗ 40.5 ± 2.3∗
WBC (×103/μL) 10.5 ± 1.3 6.3 ± 0.2 9.2 ± 1.0 7.9 ± 1.2 8.1 ± 1.5 6.0 ± 0.8
Neutrophil (%) 9.8 ± 1.9 11.7 ± 1.2 12.9 ± 1.3 15.1 ± 1.7 15.9 ± 1.7 16.3 ± 3.4
Lymphocyte (%) 78 ± 3.2 74.2 ± 1.8 72.3 ± 2.7 70.1 ± 3.2 69.7 ± 1.9 70.4 ± 3.1
Monocyte (%) 12.2 ± 1.9 14.1 ± 1.2 14.8 ± 1.5 14.9 ± 1.6 14.4 ± 0.5 13.3 ± 1.1
Platelets (×103/μL) 663 ± 138 780 ± 96 904 ± 182 679 ± 105 399 ± 52 395 ± 46
∗P < 0.01; ∗∗P < 0.001.
(a) (b)
(c) (d)
Figure 5: Photographs of open rat stomachs following 3-day administration of (a) normal saline, (b) indomethacin, (c) ZM4, and (d) ZM5.
Arrows in photograph (b) indicate examples of full mucosal ulcers induced by indomethacin treatment.6 ISRN Pharmacology
Table 2: Rats serum biochemical levels following a 10-day admin-
istration of ZM4 and ZM5.
Parameters Control ZM4 50mg/kg ZM5 50mg/kg
Cholesterol (mg/dL) 72 ± 98 6 ± 38 5 ± 5
Triglyceride (mg/dL) 61 ± 66 6 ± 79 2 ± 8∗
Total protein (g/L) 67 ± 57 5 ± 27 7 ± 2
Albumin (g/L) 41 ± 14 2 ± 14 2 ± 1
GGT (IU/L) 0.6 ± 0.2 0.6 ± 0.1 0.9 ± 0.2
GPT (IU/L) 79 ± 87 3 ± 36 7 ± 5
GOT (IU/L) 125 ± 10 125 ± 6 126 ± 4
ALP (IU/L) 561 ± 68 527 ± 57 545 ± 78
Glucose (mg/dL) 170 ± 7 177 ± 7 177 ± 5
Urea (mg/dL) 46 ± 34 3 ± 24 0 ± 2
Creatinine (mg/dL) 0.2 ± 0.0 0.2 ± 0.0 0.4 ± 0.1∗
∗P < 0.05.
4. Discussion
Pain management is considered one of the major issues of
healthcare systems worldwide. Analgesics used to treat noci-
ceptive pain traditionally follow the World Health Orga-
nization ladder, stepping through paracetamol, NSAIDs,
and ﬁnally opioids. However, neuropathic pain conditions
respond better to antidepressant and anticonvulsant classes
of medication [20]. The antinociceptive and anti-inﬂam-
matory eﬀects of NSAIDs are mainly due to their common
property of inhibiting COX enzymes involved in the for-
mation of prostaglandins. Prostaglandins are potent hyper-
algesic mediators which modulate multiple sites along the
nociceptive pathway and enhance both transduction (peri-
pheral sensitizing eﬀect) and transmission (central sensitiz-
ing eﬀect) of nociceptive information which in turn leads
to normalization of the increased pain threshold associated
with inﬂammation [21, 22]. A full inﬂammatory response,
however, is sustained by prostanoids generated by both con-
stitutive and inducible COX. The most prominent signs of
acute inﬂammation due to prostaglandin-induced vasodi-
latation and increased blood vessel permeability, erythema,
and edema have been shown to be inhibited by both non-
selective traditional NSAIDs and selective COX-2 inhibitors
through inhibition of prostaglandin synthesis [22].
Concerning analgesia, both peripherally and centrally
mediated analgesic eﬀects of our tested compounds were
investigatedinthisstudy.Theaceticacid-inducedabdominal
constriction, a behavior called writhing, generally elucidates
peripheral analgesic activity [23]. Acetic acid, which is a
common inducer of writhing syndrome in rodents [24, 25],
causes algesia by increasing the peritoneal ﬂuid level of
prostaglandins which in turn, excites the pain nerve endings.
A dose-dependent reduction in the number of writhings was
observed for ZM4 and ZM5 compounds at the high tested
dose (50mg/kg), and both compounds were equipotent to
the eﬀect of aspirin (200mg/kg). Hot plate test was also per-
formed to conﬁrm the peripheral pain inhibition of the
tested compounds as many previous studies proved the
potential of using the hot plate test in investigating the
peripheral analgesic activity of nonopioid analgesics such
as herbal drugs and NSAIDs [26]. Again, it was found that
both ZM4 and ZM5 were superior in increasing the latency
times compared to aspirin which reﬂects the ability of these
compounds to reduce peripheral pain in rodents.
On the other hand, formalin test reveals both peripheral
and central analgesic activities. It was previously reported
thatinjectingformalininrodentpawsproducesatypicalpat-
tern of two-phase pain response [17, 18]. The ﬁrst phase
(early, acute phase) starts immediately (0–5min) after
administration of formalin and corresponds to neurogenic
pain while the second phase (late, tonic phase) usually starts
15min after formalin administration and reﬂects inﬂam-
matory pain. The early phase has been proved to be sensitive
to reversal by analgesics such as opioids and paracetamol
whilethesecondphaseofresponsehasclassicallybeenlinked
to inﬂammation as NSAIDs such as aspirin, ibuprofen, and
ketoprofen that are active in reducing the associated behav-
iors [5, 6]. Since the nociception in formalin test is most
likely produced via the COX-1 as well as COX-2 pathways
in rat [27], ibuprofen rather than aspirin (irreversible COX-
1) was chosen as a positive control in current formalin
testing due to its nonselectivity in inhibiting COX enzyme.
Previously, it was reported by Daud et al. [28] that ibuprofen
can reduce signiﬁcantly the licking time of rats injected with
formalin in their paws. The reduction of pain response, that
is, licking time, in both early and late phases after the admin-
istration of ZM4 was comparable to the eﬀect of ibupro-
fen which indicates the ability of this compound to elim-
inate neurogenic and inﬂammatory pain. Conversely, ZM5
showed less pronounced activity in the late formalin phase
(P>0.05) which again reﬂects the superiority of ZM4 in
reducing acute and chronic pain. Nevertheless, such con-
clusion should not reﬂect the less anti-inﬂammatory ability
of ZM5 as we have recently reported that ZM5 showed
comparable anti-inﬂammatory eﬀects to diclofenac and
celecoxib in rat paw edema test and enhances the production
of transforming growth factor-β from T regulatory cells as
compared with other tested compounds [11, 13, 14]. There-
fore, it could be suggested that ZM5 has slow rate of absorp-
tion through gastrointestinal tract since it neither showed
any anti-inﬂammatory eﬀect during the ﬁrst hour after car-
rageenan paw edema induction nor any signiﬁcant reduction
in the late phase of formalin test. On the other hand, the
quick antinociceptive behavior and reduction of paw edema
following oral administration of ZM4 indicate its quick
absorption. Thus, pharmacokinetic studies are still war-
ranted to conﬁrm the rate and extent of oral absorption of
ZM compounds.
Both single and repeated administration of high doses
of ZM4 and ZM5 orally and intraperitoneally did not cause
any mortality or detected behavioral changes including any
impairment in motor function of the treated animals com-
pared to the control. Repeated administration of high doses
for ten days did not show any change in body weight or
any change in most of the organ weights. Furthermore, the
repeated administration did not show any signiﬁcant change
in lipid proﬁles except an unexplained rise in female trigly-
ceride level that was not apparent in males. The kidney and
liver function tests were reported normal except again theISRN Pharmacology 7
unexplained rise in creatinine levels in females only, even
though urea levels were not changed. However, increase in
RBC, HB, and PCV values was noted indicating that these
compounds could induce erythropoiesis. Further repeated
studies are warranted to explain the eﬀects and safety of ZM
compounds on the respiration, blood gases, and the bone
marrow to highlight their mechanism.
In conclusion, ZM4 and ZM5 were structured to exhibit
analgesic activity as well as to have less adverse events.
Recently, these compounds were shown to exhibit eﬀect on
enhancing anti-inﬂammatory and reducing proinﬂamma-
tory cytokines from diﬀerent population of spleen cells [14].
Such eﬀects strengthen the use of such compounds, but
more pharmacokinetic and pharmacodynamic studies are
warranted.
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